AGP Picks
View all

Vaxneuvance market seen expanding through 2035 as pneumococcal vaccination demand grows

7 hours ago
Vaxneuvance market seen expanding through 2035 as pneumococcal vaccination demand grows
By AI, Created 14:30 UTC, Nov 19, 2026, AGP -

The Business Research Company says the Vaxneuvance market is poised for steady growth through 2035, driven by broader pneumococcal vaccination programs, rising pneumonia cases and stronger R&D spending. North America held the largest share in 2025, while the report points to expanding opportunities in other regions and higher-valency vaccines.

Why it matters: - Vaxneuvance is positioned within a broader push to prevent pneumococcal disease in adults and children. - Rising vaccination coverage, higher disease burden and next-generation vaccine development are shaping demand across healthcare systems. - The market outlook matters for vaccine makers, providers and public health planners focused on invasive pneumococcal disease.

What happened: - The Business Research Company released its Vaxneuvance Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Vaxneuvance market has expanded in recent years and is expected to keep growing through 2035. - North America held the largest share of the Vaxneuvance market in 2025. - The report also covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - A free sample of the market report is available. - The full market report is also available.

The details: - Vaxneuvance is a pneumococcal conjugate vaccine designed to protect adults and children from invasive disease caused by specific Streptococcus pneumoniae strains. - The vaccine targets 15 bacterial serotypes. - The report links historical growth to routine pneumococcal vaccination programs, rising pneumococcal infections, greater public awareness, conjugate vaccine advances and better healthcare access. - Expected growth drivers include investment in next-generation vaccines, stronger focus on elderly immunization, expanded national immunization programs, higher-valency vaccines and broader adoption in developing healthcare systems. - Additional drivers include wider use of broad-spectrum pneumococcal vaccines, prevention of invasive pneumococcal disease, higher immunization coverage among children and adults, and increased focus on high-risk groups. - Pneumonia prevalence is a central tailwind for the market. - The report says pneumonia remains widespread because of viral and bacterial infections, weakened immune systems, air pollution exposure and an aging population. - The report cites Johns Hopkins University data showing an average Pneumonia Global Action Plan for Pneumonia and Diarrhea score of 56% across 15 countries in 2024, up from 54% in 2023. - The report also cites April 2025 Office for National Statistics data showing UK net R&D spending rose 8.2% year over year, from $19.9 billion in 2022 to $21.5 billion in 2023.

Between the lines: - The market narrative points to a shift from basic vaccine access toward broader, more targeted pneumococcal protection. - Stronger demand for higher-valency products suggests buyers are prioritizing broader coverage rather than narrower strain protection. - North America’s lead likely reflects mature healthcare infrastructure and high vaccine uptake, while other regions remain growth targets. - The report’s emphasis on elderly and high-risk groups signals where future demand may be concentrated.

What's next: - The Business Research Company says future growth will depend on continued vaccine innovation, wider immunization programs and adoption in developing healthcare systems. - The company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics and updated trend analysis. - The report positions broader pneumococcal prevention as a continuing priority as public health systems expand coverage.

The bottom line: - Vaxneuvance sits in a growing pneumococcal vaccine market that is being pulled by disease burden, expanded immunization and demand for broader protection.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Africa Environmental Observer

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Africa Environmental Observer

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.